TCRXNasdaq

TScan Therapeutics, Inc.

Alert me on TCRX

Insider buys, 6 months

Congress trades, 6 months

Signals, 6 months

Six months

After each filing

Dec 24, 2025 Buy Lynx1 Capital Management LP Insider

1 week

−1.9%S&P −1.0%

1 month

+7.7%S&P +0.7%

3 months

−5.0%S&P −7.9%

6 months

−6.0%S&P +7.9%

Dec 24, 2025 Buy Nichols Weston Insider

1 week

−1.9%S&P −1.0%

1 month

+7.7%S&P +0.7%

3 months

−5.0%S&P −7.9%

6 months

−6.0%S&P +7.9%

Every purchase and sale on this ticker reported by a member of Congress or an insider, measured from the close of the first trading day after it became public to the close 1 week, 1 month, 3 months and 6 months later, each beside the S&P over the same days.

Filings for TCRX

18 held · newest 518 held · newest 2

Loading the filings.

See all 18 filings for TCRX

Aeon news and offers by email

New sources, new features and offers like our founding price. A few times a month at most. Stop any time.

Signal history

No signal for this ticker yet. A signal is written when insider buying here scores one dot or more.

Stakes

Sep 21, 2026 Schedule 13G

Readout Capital, LP: 5.4%, 3,453,388 shares

Jun 30, 2026 Schedule 13G, amended

Lynx1 Capital Management LP: 13.1%, 20,519,148 shares

Jun 30, 2026 Schedule 13G, amended

BVF PARTNERS L P/IL: 10%, 6,417,831 shares

Mar 31, 2026 Schedule 13G, amended

BVF PARTNERS L P/IL: 10%, 5,578,288 shares

Schedule 13D is filed within 5 business days of crossing 5 percent by an investor who may seek to influence the company. Schedule 13G is filed by a passive holder, and a large institution has up to 45 days after the quarter end.

Government contracts, last 12 months

Awards of $10M and up, from USAspending · context, not a signal

No contracts of $10M or more in the last 12 months.

Lobbying

Last four quarters

No lobbying reports on file.